Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06422871 · ClinicalTrials.gov registry record

PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis

A clinical trial of End Stage Renal Disease and Hemodialysis Access Failure, sponsored by Merit Medical Systems.

Recruiting
Registry status
100
Enrollment target
3
Study locations

NCT06422871 is a study of End Stage Renal Disease and Hemodialysis Access Failure that is actively recruiting participants, run by Merit Medical Systems. The registered enrollment target is 100 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06422871, a study of End Stage Renal Disease and Hemodialysis Access Failure, is actively recruiting participants, sponsored by Merit Medical Systems.

RECRUITING
Registry status
100 participants
Enrollment target
3
Study locations

Study Summary

The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of their regular medical care for maintaining long-term dialysis access when all other dialysis access options have failed. If participants in the study are not seen for a standard of care clinic visit during the 4 visit timepoints over 2 years, the participant will be followed by phone to check their current health and dialysis status.

Conditions Studied

End Stage Renal Disease Hemodialysis Access Failure

Interventions

  • DEVICE HeRO® Graft System or Super HeRO® System

Study Locations (3)

Florida

  • Sarasota Memorial Health Care System - Sarasota

North Carolina

  • WakeMed - Raleigh

Texas

  • Baylor Scott & White Heart and Vascular Hospital - Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-07-28
Est. Completion 2028-12-28

Sponsor

Merit Medical Systems

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06422871

The ClinicalTrials.gov registry entry for NCT06422871 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The listed sponsor is Merit Medical Systems, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which HeRO® Graft System or Super HeRO® System is the first listed.

NCT06422871 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT06422871 about?

NCT06422871 is a clinical study titled "PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis". The goal of this observational study is to increase the understanding of the safety and performance of Merit Medical's HeRO Graft System (HeRO) and Super HeRO Adaptor and Support Seal System (Super HeRO) devices. This study includes adults that are being treated with one of these devices as part of ...

What is the current status of trial NCT06422871?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-07-28. Estimated completion is 2028-12-28.

What conditions does trial NCT06422871 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Hemodialysis Access Failure.

What interventions are being tested in trial NCT06422871?

The interventions under investigation include: HeRO® Graft System or Super HeRO® System (DEVICE).

Who is sponsoring clinical trial NCT06422871?

This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06422871 being conducted?

This trial has 3 study locations across Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

End Stage Renal Disease

All registered trials for this condition

Hemodialysis Access Failure

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.